Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/iteos-to-raise-120m-xbrane-and-stada-to-out-license-lucentis-biosimilar/
https://www.globenewswire.com/news-release/2024/05/09/2879226/0/en/Anaptys-Announces-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/05/09/2879216/0/en/Anaptys-Announces-Positive-Top-Line-GEMINI-2-Phase-3-Clinical-Trial-Results-of-Imsidolimab-IL-36R-in-Generalized-Pustular-Psoriasis-GPP.html
https://www.globenewswire.com/news-release/2024/05/09/2879197/0/en/Anaptys-to-Receive-50-Million-in-a-Capped-Non-Recourse-Monetization-from-Amended-Agreement-with-Sagard-in-Exchange-for-Additional-Jemperli-Royalties.html
https://www.globenewswire.com//news-release/2024/03/11/2844161/0/en/Anaptys-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2024/02/29/2838079/0/en/Anaptys-to-Present-at-TD-Cowen-s-44th-Annual-Health-Care-Conference-and-2024-AAD-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/01/31/2821240/0/en/Anaptys-to-Present-at-Guggenheim-s-6th-Annual-Biotechnology-Conference.html
https://www.fiercebiotech.com/biotech/anaptys-picks-rival-biogen-autoimmune-asset-centessa
https://www.globenewswire.com//news-release/2023/11/27/2786530/0/en/Anaptys-Expands-Immune-Cell-Modulator-Pipeline-with-Exclusive-License-to-BDCA2-Modulator-Antibody-Portfolio-from-Centessa-Pharmaceuticals.html
https://www.globenewswire.com//news-release/2023/11/07/2775654/0/en/Anaptys-Named-a-BioSpace-2024-Best-Places-to-Work-Winner.html